Breaking News

Financial Report: Sanofi

Loss of $205 million to generic competition in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi 2Q Revenues: $11.2 billion (flat) 2Q Earnings: $1.5 billion (flat) YTD Revenues: $21.9 billion (-6%) YTD Earnings: $3.9 billion (+15%) Comments: Pharmaceutical sales were flat at $9.4 billion. Sales lost to generic competition were $205.0 million in the quarter (Lovenox, Xatral and Taxotere in the U.S., and Taxotere, Plavix and Aprovel in the EU). Eloxatin sales were up 36% to $471.6 million. Diabetes revenue was up 14% driven by Lantus sales, up 17% to $1.5 billion. Vaccines sales w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters